2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2274 Localized radiation for extramedullary disease prior to ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: Clinical outcomes and CAR-T expansion

Saurabh Zanwar, MBBS, MD, Christoph Schaefers, MD2, William Breen, MD3, Khaled Aziz, MD, PhD4, Melinda Tan, MD5, Moritz Binder, MD, MPH6, Wilson Gonsalves, MD7, Nadine Abdallah I, MD8, Saurabh Chhabra, MD, MBBS9, Ricardo Daniel Parrondo, MD10, Morie Gertz11, Taxiarchis Kourelis, MD12, Rahma Warsame, MD13, Joselle M Cook, M.D.14, Andre De Menezes Silva Corraes, MD15, Malvika Gupta, MD16, Udit Yadav, MBBS17, P. Leif Bergsagel, MD18, J Erin Wiedmeier-Nutor, MD,MPH19, Rafael Fonseca, MD20, Sikander Ailawadhi, MD21, Prashant Kapoor, MD22, Shaji Kumar, MD23, Yi Lin Jr, MD, PhD24
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Scottsdale, Arizona, United States
10 Mayo Clinic, Jacksonville, Florida, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Scottsdale, Arizona, United States
18 Mayo Clinic, Scottsdale, Arizona, United States
19 Mayo Clinic, Scottsdale, Arizona, United States
20 Mayo Clinic, Scottsdale, Arizona, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States

Background: Extramedullary disease (EMD) is associated with poor prognosis and inferior outcomes following B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed/refractory multiple myeloma (RRMM). Radiation therapy (RT) provides effective local control in EMD and has been proposed as a bridging strategy, but existing evidence is limited by retrospective analyses, heterogeneous radiation timing and dosing, and use of differing CAR-T products.  Additionally, the effect of RT delivered immediately before CAR-T infusion on CAR-T expansion remains unknown. We evaluated the feasibility, safety, and clinical impact of standardized RT delivered immediately before ciltacabtagene autoleucel (cilta-cel) infusion in patients with EMD, including its effects on CAR-T expansion and clinical outcomes.

Methods: We performed a retrospective cohort study of patients with RRMM and documented EMD who underwent standard-of-care BCMA-directed CAR-T therapy with cilta-cel between April 2022 and March 2026. Patients receiving localized bridging RT to EMD lesions (EMD-RT) were compared with those who did not receive RT (EMD-noRT) and the non-EMD cohort. RT was delivered to the dominant EMD lesion(s) on days -2 and -1 before CAR-T infusion (4 Gy in 2 fractions), per institutional practice and at the discretion of the treating radiation oncologist. Baseline demographic, disease, and treatment characteristics were collected. Clinical outcomes included PET complete response at 3 months, progression-free survival (PFS), overall survival (OS), and treatment-related toxicity, and were compared between the EMD-RT and EMD-noRT cohorts. Day 14 peripheral blood CAR+ T-cell levels were assessed by flow cytometry in a subset of patients with EMD (with and without RT) and compared with patients without EMD.

Results: Among 463 patients treated with cilta-cel, 90 (19.4%) had EMD, including 11 (12.2%) who received pre-infusion RT (EMD-RT). Median age was 71 years (range, 53-89) in the EMD-RT cohort and 63 years (range, 33-82) in the EMD-noRT cohort. Males comprised 91% and 60.7% of the EMD-RT and EMD-noRT cohorts, respectively. Patients in the EMD-RT cohort had received a median of 3 prior lines of therapy (range, 1-3) versus 4 (range, 1-14) in the EMD-noRT cohort. At 3 months, PET complete response was achieved in 80% (n=8) of the EMD-RT cohort and 73% (n=48) of the EMD-noRT cohort.

Median follow-up was 6.8 months (95% CI, 4.5-12.9) for EMD-RT and 14.8 months (95% CI, 11.7-18.3) for EMD-noRT. Six-month PFS was 90.9% and 76.7%, respectively, with a median PFS of 10.9 months (95% CI, 7.5-not reached) versus 14.9 months (95% CI, 8.8-20.2; p=0.40). In contrast, median PFS was not reached in patients without EMD (6-month PFS, 93%; p<0.001). Median OS was not reached in either EMD cohort, and 6-month OS was 100% for EMD-RT and 90.1% for EMD-noRT (p=0.94).

The highest cytokine release syndrome (CRS) grade in the EMD-RT cohort was grade 1 (70%). In the EMD-noRT cohort, 53% experienced grade 1 CRS, 18% grade 2 CRS, and one patient grade 3 CRS. No parkinsonian neurotoxicity occurred in the EMD-RT cohort, whereas two patients (2.5%) in the EMD-noRT cohort developed parkinsonian neurotoxicity. Grade 2 ICANS was noted in 1 (9%) patient in EMD-RT and 5 (7%) patients in EMD-noRT cohort. No unexpected RT-related adverse events or delays in CAR-T infusion were observed.

Day 14 CAR+ T-cell levels were significantly lower in patients with EMD than in non-EMD controls (median 196 vs. 393 cells/µL; n=25 vs. 44; p=0.025). The CAR CD4/CD8 ratio was similar between groups, with CD8 predominance. Among patients with EMD and available day 14 samples, median CAR+ T-cell levels were 75 cells/µL in the EMD-RT cohort (n=5) and 214 cells/µL in the EMD-noRT cohort (n=20; p=0.77). Additional flow cytometry analyses are planned.

Conclusions: Localized RT delivered on day -2 and day -1 immediately before CAR-T infusion is a feasible bridging strategy for patients with EMD and was not associated with increased toxicity. No clear clinical benefit of RT before cilta-cel was observed, although the small sample size and limited follow-up, particularly in the RT cohort, limit interpretation. Day 14 CAR T-cell levels were lower in patients with EMD, warranting further investigation as a potential mechanism for their inferior outcomes. Prospective studies are needed to define the optimal role, timing, and patient selection for RT before CAR-T.

Saurabh Zanwar, MBBS, MD: International Waldenstrom Macroglobulinemia Foundation - Research Funding; International Myeloma Society - Research Funding